299 related articles for article (PubMed ID: 17013085)
21. Tumor immunotherapy in melanoma: on the dawn of a new era?
Wilcox R; Markovic SN
Curr Opin Mol Ther; 2007 Feb; 9(1):70-8. PubMed ID: 17330404
[TBL] [Abstract][Full Text] [Related]
22. Despite past disappointments, the future of melanoma therapy appears bright.
Tarhini A
Oncology (Williston Park); 2009 May; 23(6):509, 515. PubMed ID: 19544692
[No Abstract] [Full Text] [Related]
23. The unfulfilled promise of melanoma vaccines.
Livingston P
Clin Cancer Res; 2001 Jul; 7(7):1837-8. PubMed ID: 11448892
[No Abstract] [Full Text] [Related]
24. Immunotherapy of malignant melanoma.
Roenigk HH
Compr Ther; 1975 Aug; 1(4):65-70. PubMed ID: 1220917
[No Abstract] [Full Text] [Related]
25. Immunotherapy of melanoma.
Chapman PB
Cancer Chemother Biol Response Modif; 2002; 20():371-83. PubMed ID: 12703215
[No Abstract] [Full Text] [Related]
26. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
27. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of melanoma.
Smith C; Cerundolo V
Immunology; 2001 Sep; 104(1):1-7. PubMed ID: 11576213
[No Abstract] [Full Text] [Related]
29. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Peggs KS; Quezada SA; Korman AJ; Allison JP
Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
[TBL] [Abstract][Full Text] [Related]
30. [Immunology of melanoma].
Vanwijck R; Bernheim JL; Lejeune FJ
Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
[No Abstract] [Full Text] [Related]
31. Immunotherapy of melanoma: an update.
Homsi J; Grimm JC; Hwu P
Surg Oncol Clin N Am; 2011 Jan; 20(1):145-63. PubMed ID: 21111964
[TBL] [Abstract][Full Text] [Related]
32. [Immunological aspects of melanoma].
Sjögren H
Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
[No Abstract] [Full Text] [Related]
33. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
34. Cell transfer and other immunotherapeutic strategies.
Rosenberg SA
Clin Adv Hematol Oncol; 2005 Jan; 3(1):28-9. PubMed ID: 16166964
[No Abstract] [Full Text] [Related]
35. Vaccines against advanced melanoma.
Blanchard T; Srivastava PK; Duan F
Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
[TBL] [Abstract][Full Text] [Related]
36. [Clinical application of monoclonal antibodies to human malignant melanoma-associated antigens].
Kageshita T; Ishihara K
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1744-8. PubMed ID: 3899015
[TBL] [Abstract][Full Text] [Related]
37. Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?
Ferretti G; Felici A; Pino MS; Cognetti F
J Clin Oncol; 2006 Dec; 24(34):5469-70; author reply 5470-1. PubMed ID: 17135653
[No Abstract] [Full Text] [Related]
38. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.
Grange JM; Krone B; Stanford JL
Eur J Cancer; 2009 Sep; 45(13):2266-73. PubMed ID: 19497734
[TBL] [Abstract][Full Text] [Related]
40. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
Jack A; Boyes C; Aydin N; Alam K; Wallack M
Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
